Form 8-K · Current report
Cencora 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001140859
- Accession no.
- 0001140859-26-000032
Summary
Cencora reported fiscal 2026 third-quarter revenue of $84.8 billion, up 5.1 percent year over year, with GAAP diluted EPS of $3.94 and adjusted diluted EPS of $4.48, and raised its full-year adjusted diluted EPS guidance to $17.75–$17.95 from $17.70–$17.90. CEO Robert P. Mauch attributed the results to the company's pharmaceutical-centric strategy and said the raised outlook reflected confidence in the business; Cencora also repurchased $1 billion of shares during the quarter.
Key points
- Third-quarter revenue rose 5.1 percent year over year to $84.8 billion, with U.S. Healthcare Solutions revenue up 4.9 percent and International Healthcare Solutions revenue up 5.9 percent.
- GAAP diluted EPS was $3.94 versus $3.52 a year earlier; adjusted diluted EPS rose 12.0 percent to $4.48.
- Gross profit margin expanded 66 basis points to 4.26 percent, helped by the February 2026 OneOncology acquisition and partly offset by higher sales of lower-margin GLP-1 products.
- Cencora repurchased $1 billion of shares in the quarter, and held a conference call and webcast on August 5, 2026 at 8:30 a.m. Eastern time.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 5, 2026, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended June 30, 2026. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under Item 7.01 below, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.